Table of Contents
Personalized islet cell transplantation therapies represent one of the most promising frontiers in diabetes treatment, offering the potential to restore natural insulin production and fundamentally transform the lives of millions of people living with type 1 diabetes. As biomedical research continues to advance at an unprecedented pace, the dream of tailored, patient-specific treatments that address individual immune profiles and metabolic needs is rapidly becoming a reality. This comprehensive exploration examines the current state of islet cell transplantation, the revolutionary personalization strategies being developed, and the transformative innovations that promise to make this therapy more effective, accessible, and sustainable in the coming years.
Understanding Islet Cell Transplantation and Its Clinical Significance
Type 1 diabetes is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas, leading to insulin deficiency and chronic hyperglycemia. The main current therapeutic strategies for clinically overt type 1 diabetes—primarily exogenous insulin administration combined with blood glucose monitoring—fail to fully mimic physiological insulin regulation, often resulting in suboptimal or insufficient glycemic control. Despite the use of cutting-edge diabetes technologies, more than 40% of individuals with type 1 diabetes still do not reach the glycemic target of HbA1c below 7%, and around 20% of them experience severe hypoglycemic events annually, with one-third reporting hypoglycemia unawareness.
Islet cell transplantation has emerged as a promising avenue for functionally replacing endogenous insulin production and achieving long-term glycemic stability. The procedure involves transferring insulin-producing islet cells from a donor pancreas into a patient with diabetes, with the goal of restoring the body’s natural ability to regulate blood sugar levels. More than 2,000 individuals have been treated with allogeneic islet transplants. Phase 3 trials of transplantation of deceased donor islets documented the effectiveness of transplanted islets in restoring near-normoglycemia, glycemic stability, and protection from severe hypoglycemia, with an acceptable safety profile for the enrolled high-risk population.
Lantidra became the only therapy approved by the U.S. Food and Drug Administration to treat brittle type 1 diabetes. Pancreatic islet cell therapy is a treatment approved by the FDA only for adults with type 1 diabetes who struggle to control their blood sugar due to frequent episodes of severe low blood sugar and hypoglycemia unawareness, or being unable to detect that blood sugar is dropping. A patient who received the transplant was able to stop taking daily, life-saving insulin injections, and this was the third time the patient received an islet cell transplant, with the first two procedures in 2011 allowing him to live without insulin injections for 12 years.
Current Challenges in Islet Cell Transplantation
While islet cell transplantation has demonstrated remarkable clinical success, several significant challenges continue to limit its widespread application and long-term effectiveness. Understanding these obstacles is essential for appreciating the importance of personalized approaches to this therapy.
Limited Donor Availability and Organ Shortage
The widespread application of islet transplantation is significantly constrained by the limited availability of pancreata from deceased donors, yet millions of individuals with type 1 diabetes stand to benefit from islet cell replacement therapy. The limited availability of donors leads to prolonged waiting periods for patients in need, and the necessity for multiple transplantations to achieve satisfactory outcomes. More than 1.4 million people in the United States have type 1 diabetes, with roughly 80,000 people having brittle type 1 diabetes, a more severe form of type 1 diabetes. This stark disparity between the number of patients who could benefit from islet transplantation and the available donor organs represents one of the most pressing challenges in the field.
Immune Rejection and the Need for Immunosuppression
Islet transplantation is a promising therapy for insulin-dependent diabetes, however, immune rejection and insufficient vascularization hinder the survival and function of transplanted islets. The currently approved islet-transplant method infuses islets into a vein in the liver, an invasive procedure that requires the long-term use of immune-suppressing drugs to prevent islet rejection, involves the relatively uncontrolled dispersal of islets, and usually becomes ineffective within a few years, likely in part to the lack of proper support cells.
Islet transplant patients are required to undergo intensive life-long immunosuppression to prevent graft rejection and loss of islet function, and the selection of immunosuppressants used may induce side effects or autoimmunity recurrence, which will influence islet transplantation outcome. Intensive immunosuppression is required to prevent immune rejection of the graft, which may in turn lead to undesirable side effects such as toxicity to the islet cells, kidney toxicity, occurrence of opportunistic infections, and malignancies. Tacrolimus-based immunosuppression is effective against allo- and auto-immune rejection, but its side effects include nephrotoxicity and diabetogenicity due to effects on the islet cells.
Transplantation Site Limitations and Vascularization Issues
Transplanting islets into the subcutaneous space rather than the portal vein is advantageous because this site is easier and safer to use, however, transplantation of islets directly or within planar devices has been unsuccessful in humans, mainly because of the low oxygen torr in the subcutaneous space. The lack of adequate blood vessel formation and oxygen supply to transplanted islets represents a critical barrier to successful engraftment and long-term function. Without proper vascularization, islet cells cannot receive the nutrients and oxygen they need to survive and produce insulin effectively.
Autoimmune Recurrence in Type 1 Diabetes
Curing or preventing diabetes caused by autoimmunity, in which the immune system spontaneously destroys its own islet cells, is called Type 1 diabetes, and the transplanted islet cells in the autoimmune mice have two targets on their backs: not only are they foreign, but they are vulnerable to autoimmune attack by a misguided immune system bent on destroying islet cells. Autologous stem cell transplantation would not prevent progression of the autoimmune disease and would likely require additional immune modifying strategies to prevent autoimmune-mediated rejection of the graft tissue. This dual challenge of preventing both allograft rejection and autoimmune destruction makes islet transplantation in type 1 diabetes particularly complex.
The Promise of Personalized Medicine in Islet Transplantation
Personalized medicine approaches are revolutionizing islet cell transplantation by tailoring treatments to individual patient characteristics, immune profiles, and specific disease mechanisms. These customized strategies aim to improve transplant outcomes, reduce complications, and ultimately make this life-changing therapy available to more patients.
Genetic Profiling and Immune Compatibility Assessment
Genetic profiling represents a cornerstone of personalized islet transplantation, enabling clinicians to identify patient-specific immune responses and optimize donor-recipient matching. Understanding the mechanisms of immune recognition and rejection involves antigen presentation of major histocompatibility complex (MHC) molecules (also known as human leukocyte antigen [HLA] in humans) to T cells. By analyzing a patient’s HLA profile and immune characteristics, medical teams can better predict the likelihood of rejection and customize immunosuppressive protocols accordingly.
Starting stem cell sources include human induced pluripotent stem cells (hiPSCs) that have been genetically engineered to avoid the host immune response, curated HLA-selected donor hiPSCs that can be matched with recipients within a given population, and multipotent stem cells with natural immune privilege properties. This approach allows for the creation of cell banks with diverse HLA profiles that can be matched to a broader range of recipients, potentially reducing rejection rates and the need for intensive immunosuppression.
This will enable the future development of multidimensional evaluation frameworks for personalized transplantation protocols, transitioning transplantation medicine from a morphology-based diagnostic model to a new era of molecular endophenotyping based on precise molecular signatures. Advanced single-cell sequencing technologies are providing unprecedented insights into the cellular and molecular mechanisms underlying graft rejection and tolerance, enabling more precise personalization of treatment strategies.
Customized Immunosuppression Protocols
Rather than applying a one-size-fits-all approach to immunosuppression, personalized protocols are being developed based on individual patient immune profiles and risk factors. Immunosuppressants influence the profile of regulatory T cells (Tregs), which are an important subset of immunomodulatory T cells responsible for promoting immune tolerance, and immunosuppressants that foster a richer Tregs environment could drive tolerance and further minimize the need for immunosuppression.
Daclizumab (non-depleting monoclonal anti-interleukin-2 receptor antibody) and/or anti-thymocyte globulin is administered as pre-procedural induction immunosuppression, whereas low-dose tacrolimus (calcineurin inhibitor) in combination with mycophenolate mofetil or sirolimus is prescribed for maintenance immunosuppression. However, personalized approaches are moving beyond these standard regimens to tailor drug selection, dosing, and duration based on individual patient characteristics, monitoring biomarkers, and real-time assessment of immune responses.
Stem Cell Technology: Creating Patient-Specific Islet Cells
One of the most transformative advances in personalized islet cell transplantation is the development of stem cell-derived insulin-producing cells. This technology addresses the critical shortage of donor islets while enabling the creation of patient-specific or immunologically compatible cells.
Pluripotent Stem Cell-Derived Beta Cells
To overcome the challenge of the scarcity of donor-derived islets, researchers have investigated human pluripotent stem cells (hPSCs) as a scalable source for generating islet cells, and certain products developed in this rapidly advancing field have recently progressed to the stage of clinical trials, highlighting the potential of stem cell-derived islets in developing sustainable and effective diabetes treatments.
These achievements amplified academic and industry efforts to generate pluripotent stem cell–derived β-cells through directed differentiation for β-cell replacement, and preliminary results of ongoing clinical trials suggest that the transplantation of stem cell–derived β-cells can consistently restore insulin independence in immunosuppressed recipients with type 1 diabetes, thus signaling the profound progress made in generating an unlimited and a uniform supply of cells for transplant.
Zimislecel is an allogeneic stem cell–derived islet-cell therapy, and data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. Clinical trials are currently evaluating the safety and efficacy of these stem cell-derived products, with promising early results demonstrating the ability to restore glycemic control and reduce or eliminate the need for exogenous insulin.
Induced Pluripotent Stem Cells for Personalized Therapy
There were no significant functional differences between beta cells derived from type 1 diabetes patients and those from non-diabetic individuals, underscoring the potential for personalized cell-based therapies. This finding is particularly significant because it demonstrates that patient-specific cells can be generated and differentiated into functional insulin-producing cells, opening the door to truly personalized autologous transplantation approaches.
An investigator-initiated clinical trial is set to commence in early 2025 at Kyoto University Hospital, and the trial will involve the transplantation of OZTx-410 into the abdominal region of three individuals with insulin-deficient type 1 diabetes at high risk for severe hypoglycemia. OZTx-410 is a sheet of pancreatic islet-like cells, differentiated from clinical-grade iPS cells. These clinical trials represent important milestones in translating stem cell technology into personalized diabetes treatments.
In the case of autologous iPS cell transplantation, the preclinical safety tests and procedures needed to establish and differentiate individual iPSCs entail significant financial and time costs for each patient, so the approach of transplanting allogeneic iPSCs, which have established safety profiles, while administering immunosuppressive drugs to prevent rejection was initially adopted. Reducing the cost barrier for using stem cells in islet transplantation will likely necessitate large scale stock production which may not align with personalized strategies such as using autologous stem cells where on demand production is inherently required.
Optimizing Stem Cell Differentiation Protocols
Selection for CD26− and CD49A+ cells from stem cell-derived islet-like clusters improves therapeutic activity in diabetic mice, and these cells were derived from a clinical-grade line of hESCs, with a differentiation protocol adapted to up-scalable bioreactors. Researchers are continuously refining differentiation protocols to generate more functional, mature, and therapeutically effective insulin-producing cells from stem cell sources.
When transplanted into diabetic mouse models, these cells effectively controlled blood glucose levels, demonstrating their functional maturity. The ability to generate large quantities of functional beta cells through optimized differentiation protocols represents a major step toward making personalized islet cell therapy scalable and clinically viable for widespread use.
Gene Editing and Hypoimmunogenic Cell Engineering
Gene editing technologies, particularly CRISPR-Cas9, are enabling the creation of “universal donor” islet cells that can evade immune recognition and rejection. This approach represents a paradigm shift in personalized medicine, potentially eliminating the need for perfect HLA matching and intensive immunosuppression.
Creating Immune-Evasive Islet Cells
Recent studies have focused on generating universally compatible hypoimmunogenic islets by silencing or deleting HLA genes or genes crucial for HLA expression and function, and by expressing genes encoding immune-modulatory molecules, and these cells can be engineered to express human leukocyte antigen (HLA)-negative profiles, while overexpressing immunoregulatory factors such as CD47, PD-L1, and HLA-G to evade T cell and natural killer (NK) cell immune-mediated responses.
Immune-evasive hPSC-derived islet cells can be developed through genome-editing of the hiPSC source to knock out MHC class I and II molecules and knock in other immunomodulatory markers to evade different T cell and NK cell recognition, creating a tolerogenic microenvironment for allogeneic transplantation, and when transplanted in humanized diabetic mouse models, unedited allogeneic hiPSC-derived islet cells face graft rejection, whereas hypoimmunogenic allogeneic hiPSC-derived islet cells survive and are able to rescue diabetes to achieve normal blood glucose levels in mice.
Several studies have demonstrated that inactivating B2M to disable HLA class I antigen presentation and evade T cell recognition could prolong graft survival, and after 30 days, B2m−/− allografts survived in 9 out of 15 mice, with lymphocyte infiltration observed in 2, compared with a complete rejection of all wild-type allografts. These findings demonstrate the powerful potential of gene editing to create islet cells that can survive and function without triggering immune rejection.
Combining Gene Editing with Immunomodulatory Strategies
A recent study demonstrated a novel approach to overcoming graft immune rejection by co-engineering hPSCs and Tregs, by engineering hPSCs to express a truncated epidermal growth factor receptor (EGFRt) and generating chimeric antigen receptor (CAR)-Tregs targeting EGFRt, researchers achieved localized immune protection, and this strategy effectively suppressed immune responses and protected SC-pancreatic beta-like cell grafts in vivo, providing proof of concept for combining hPSC and Treg engineering to enhance transplantation outcomes.
Gene editing and immune evasion represent a new horizon for islet transplantation, improving graft acceptance, reducing reliance on immunosuppressive drugs, and addressing donor shortages. Ongoing research focuses on the development of genetically modified ESC- or iPSC-derived islet cells with immune evasion properties, as well as the creation of more efficient, cost-effective protocols for the differentiation and expansion of these cells.
Off-the-Shelf Universal Donor Cells
These modifications aim to generate “off-the-shelf” islet cell therapies compatible with a wide range of patients, potentially eliminating the need for immunosuppressants. The development of universal donor cells represents a major advancement in personalized medicine, as these cells could be manufactured at scale, stored, and made available to patients when needed, without requiring patient-specific customization or extensive HLA matching.
Research on genetic modification has shown promise for improving immune evasion, nonetheless, continued research will be necessary to elucidate additional genomic targets that may improve upon current strategies or target other branches of the immune system involved in graft rejection. As our understanding of immune recognition mechanisms deepens, researchers are identifying new targets for gene editing that can further enhance the immune-evasive properties of transplanted islet cells.
Biomaterials and Encapsulation Technologies
Advanced biomaterials and encapsulation devices are being developed to protect transplanted islet cells from immune attack while allowing them to sense glucose and secrete insulin. These technologies represent a complementary approach to gene editing and immunosuppression for achieving immune protection.
Macroencapsulation Devices
Human islets are more viable in macroencapsulation devices than on standard culture plates. Macroencapsulation devices are designed to create a protective barrier around islet cells while allowing the passage of nutrients, oxygen, glucose, and insulin. These devices can be implanted in more accessible locations such as the subcutaneous space, potentially simplifying the transplantation procedure and improving safety.
An encapsulated pig islet IND has been filed and approved for islet transplantation, and clinical results are expected to be released in the course of 2025. This development demonstrates the potential of encapsulation technology not only for human islets but also for xenotransplantation approaches using animal-derived cells, which could further address the donor shortage problem.
Immunomodulatory Biomaterials
In situ biomaterial-mediated delivery of a streptavidin-containing chimeric form of PD-L1 (SA-PD-L1) delayed graft rejection in islet transplantation models, and this immunomodulatory effect relies on graft remodeling for “M2” like macrophages and anergic cytotoxic T cells, as shown by graft and local lymph node assessments. These biomaterials actively modulate the local immune environment to promote tolerance rather than simply providing a physical barrier.
Graft survival and metabolic function were significantly prolonged over 60 days in recipients of syngeneic islets receiving the biomaterial-delivered immunotherapy, but not in control animals, and the biomaterial-mediated PD-L1 immunotherapy resulted in delayed allograft rejection in diabetic NOD mice as compared to controls. These findings suggest that biomaterial-based immunomodulation could reduce or potentially eliminate the need for systemic immunosuppression.
Scaffolds for Enhanced Vascularization
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study, and the new approach, which requires further development and testing, could someday enable the much wider use of islet transplants to cure diabetes.
R-VECs did adapt when co-transplanted with islets, supporting the islets with a rich mesh of new vessels and even taking on the gene activity “signature” of natural islet endothelial cells, and a substantial majority of diabetic mice transplanted with islets-plus-R-VECs regained normal body weight and showed normal blood glucose control even after 20 weeks—a period that for this mouse model of diabetes suggests an effectively permanent islet engraftment. This vascularization approach addresses one of the critical challenges in islet transplantation by ensuring adequate blood supply to support islet survival and function.
This work lays the foundation for subcutaneous islet transplants as a relatively safe and durable treatment option for type 1 diabetes. The ability to transplant vascularized islets into the subcutaneous space would represent a major advancement, making the procedure less invasive and more accessible to patients.
Immune Tolerance Strategies: Moving Beyond Immunosuppression
The ultimate goal of personalized islet cell transplantation is to achieve immune tolerance—a state in which the recipient’s immune system accepts the transplanted cells as “self” without requiring ongoing immunosuppression. Several innovative strategies are being developed to accomplish this ambitious objective.
Chimeric Immune System Approaches
A combination blood stem cell and pancreatic islet cell transplant from an immunologically mismatched donor completely prevented or cured Type 1 diabetes in mice in a study by Stanford Medicine researchers. Nine out of nine mice that had developed long-standing Type 1 diabetes were cured of their disease by the combined blood stem cell and islet transplantation.
The result is a hybrid immune system, made up of both donor and recipient stem cells, and a reduced likelihood of graft-versus-host disease, and the hybrid, or chimeric, immune system is also less likely to reject the transplanted organ, particularly if it is immunologically well matched. We need to not only replace the islets that have been lost but also reset the recipient’s immune system to prevent ongoing islet cell destruction, and creating a hybrid immune system accomplishes both goals.
Adding a drug used to treat autoimmune diseases to the pre-transplant regimen, then transplanting blood stem cells, resulted in an immune system made up of cells from both the donor and the recipient and prevented development of Type 1 diabetes in 19 out of 19 animals. Because the antibodies, drugs and low-dose radiation the researchers administered to the mice are already used in the clinic for blood stem cell transplantation, the researchers believe that translating the approach to people with Type 1 diabetes is a logical next step.
Gentler Conditioning Regimens
The April study incorporated two additional drug agents that target and deplete stem cells in the recipient animal’s bone marrow, clearing the way for the transplanted stem cells to engraft and thrive in their new home and allowing the researchers to significantly reduce the radiation dose required for successful transplantation to 10 cGy, and five out of five mice with induced diabetes were cured of the disease, remained fertile and showed no signs of graft-versus-host disease.
Kim and his colleagues experimented with a three-pronged approach to prepare diabetic recipients for the stem cell transplant, combining low-dose radiation, one dose of an antibody that selectively targets and kills blood stem cells (which give rise to immune cells), and another antibody that targets mature immune cells called T cells, and they found that was enough to allow the donor cells to establish themselves in the animals’ bone marrow and create a fully functioning, chimeric immune system without the severe side effects seen with other methods.
The mice were no more susceptible to infection than control mice, showing their immune systems were functioning normally, and they could breed and give birth to healthy pups. These findings demonstrate that it is possible to achieve immune tolerance without compromising overall immune function or causing severe side effects.
Regulatory T Cell-Based Therapies
These atlases have also uncovered the complex regulatory networks that mediate immune tolerance, composed of regulatory T cells and specific macrophage subpopulations. Regulatory T cells (Tregs) play a crucial role in maintaining immune tolerance and preventing autoimmune responses. Strategies to expand or enhance Treg function are being explored as a means of promoting acceptance of transplanted islet cells.
Some research efforts combine stem cell-derived islet transplantation with novel immunotherapies designed to retrain the immune system to tolerate beta cells, and this approach could enhance the durability of the grafts while minimizing the need for immunosuppression, as immune modulation strategies aim to create a more favorable environment for the transplanted beta cells, preventing autoimmune destruction.
Alternative Transplantation Sites and Innovative Delivery Methods
Researchers are exploring alternative transplantation sites and delivery methods that could improve islet survival, function, and accessibility while reducing complications associated with traditional portal vein infusion.
Subcutaneous Transplantation
Transplanting islets into the subcutaneous (SC) space rather than the portal vein is advantageous because this site is easier and safer to use. The subcutaneous space offers several advantages, including easier access for implantation and potential retrieval, reduced invasiveness, and the ability to monitor the graft more easily. However, challenges related to oxygen supply and vascularization must be overcome for this approach to be successful in humans.
This work lays the foundation for subcutaneous islet transplants as a relatively safe and durable treatment option for Type 1 diabetes. Translation of this technology to treat patients with type 1 diabetes will require circumventing numerous hurdles, including scaling up sufficient numbers of vascularized islets, and devising approaches to avoid immunosuppression, and this study is the first step to achieve these goals, which could be within reach in the next several years.
Spleen as a Transplantation Site
Islet transplants growing in tissue-remodeled spleens restore normoglycemia in diabetic mice and macaques. The spleen represents an intriguing alternative transplantation site due to its rich blood supply and unique immunological properties. Researchers are developing methods to prepare the spleen to serve as an optimal environment for islet engraftment and function.
Omental Pouch and Other Sites
Various other anatomical sites are being investigated for islet transplantation, including the omental pouch, intramuscular sites, and engineered tissue pockets. Each site offers unique advantages and challenges in terms of vascularization, immune environment, accessibility, and monitoring capabilities. Personalized approaches may involve selecting the optimal transplantation site based on individual patient anatomy, immune status, and clinical circumstances.
Advanced Monitoring and Precision Medicine Tools
Personalized islet cell transplantation requires sophisticated monitoring tools to assess graft function, detect early signs of rejection, and guide treatment adjustments. Recent technological advances are enabling more precise, non-invasive monitoring of transplanted islets.
Single-Cell Sequencing and Multi-Omic Profiling
Capitalizing on high-dimensional, multiomic technologies for deep profiling of graft-directed immunity and the fate of the graft will provide new insights that promise to translate into sustaining functional graft survival long-term. The high-dimensional, multiomic monitoring of immunity to transplanted islets and of the fate of the islet graft will facilitate the identification of determinants of sustained islet graft function and of patients most likely to benefit from cell replacement therapies.
Single-cell sequencing technologies are fundamentally revolutionizing our understanding of transplantation biology by providing high-resolution cellular and molecular maps of graft rejection, immune tolerance, and injury, and this review systematically summarizes the application of technologies such as single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics in solid organ and islet transplantation, aiming to elucidate the mechanisms that determine graft fate.
Single-cell analyses have revealed profound insights unattainable by traditional methods, such as identifying key effector cell subpopulations—clonally expanded CD8+ tissue-resident memory T cells (TRM)—in acute rejection, and discovering new pathogenic pathways in chronic dysfunction, like antibody production driven by innate-like B cells. These insights are enabling the development of more targeted interventions to prevent rejection and promote long-term graft survival.
Non-Invasive Monitoring Approaches
This technology has pioneered new clinical applications, including non-invasive monitoring through urinary single-cell sequencing and pre-transplant quality assessment of donor organs. Non-invasive monitoring methods are particularly valuable for personalized medicine, as they allow for frequent assessment of graft status without subjecting patients to invasive procedures.
Biomarkers such as donor-derived cell-free DNA, circulating immune cells, cytokines, and metabolites are being investigated as indicators of graft health and immune responses. These biomarkers could enable early detection of rejection episodes, allowing for timely intervention before significant graft damage occurs.
Artificial Intelligence and Predictive Modeling
Artificial intelligence and machine learning algorithms are being applied to integrate complex multi-omic data, clinical parameters, and imaging information to predict transplant outcomes, identify patients at high risk for rejection, and optimize treatment protocols. These computational tools are essential for translating the vast amounts of data generated by modern monitoring technologies into actionable clinical insights for personalized care.
Xenotransplantation: Porcine Islets as an Alternative Source
Given the severe shortage of human donor islets, xenotransplantation using genetically modified porcine islets represents another potential solution that could be personalized based on patient needs and immune profiles.
Clinical trials testing pig islets in humans began as early as 2009 in New Zealand by Living Cell Technology, and the results demonstrated some positive outcomes, including improved blood sugar control and reduced insulin requirements, however, these trials did not achieve long-term islet graft function or complete insulin independence. While early results have been mixed, ongoing research is addressing the immunological and functional challenges associated with xenotransplantation.
Genetic modifications to porcine islets aim to reduce immunogenicity, prevent hyperacute rejection, and improve functional compatibility with human physiology. Encapsulation technologies are also being combined with xenotransplantation to provide additional immune protection. As these technologies mature, personalized approaches may involve selecting between human stem cell-derived islets and xenogeneic sources based on individual patient factors, availability, and clinical circumstances.
Clinical Translation and Regulatory Pathways
The translation of personalized islet cell transplantation therapies from laboratory research to clinical practice requires navigating complex regulatory pathways and addressing practical implementation challenges.
FDA Approval and Regulatory Framework
This opinion paper explores the path forward for islet transplantation as a cell therapy for type 1 diabetes, following the Biologics License Application (BLA) approval, and the authors review key challenges and opportunities that lie ahead, discussing the significance of this approval and the critical steps necessary to broaden patient access, such as scaling up production, clinical integration, reimbursement frameworks, post-marketing surveillance, and patient education initiatives.
The approval of LANTIDRA as an allogeneic cell transplant for uncontrolled type 1 diabetes marks the beginning of new chapters in improving islet transplantation. This regulatory milestone has paved the way for additional personalized islet cell therapies to enter clinical development and seek approval.
Scaling Production and Infrastructure
Key challenges remain, including pancreas allocation and UNOS compliance, expanding the number of qualified centers to meet the growing demand for islet isolation, and it is an urgent task to establish additional isolation facilities nationwide to prevent potential pancreatic ischemia-reperfusion injuries and efficiently utilize pancreas organs, which is expected between 2025 and 2026.
For stem cell-derived personalized therapies, establishing Good Manufacturing Practice (GMP) facilities capable of producing clinical-grade cells at scale is essential. This infrastructure must support both allogeneic “off-the-shelf” products and potentially patient-specific autologous therapies, requiring flexible manufacturing platforms and robust quality control systems.
Cost Considerations and Healthcare Economics
Potential adverse effects from immunosuppressive agents and the high cost and lengthy preparation time associated with patient-specific iPSC-derived islet cells represent significant barriers to widespread adoption of personalized islet cell therapies. However, the long-term cost-effectiveness of these therapies must be evaluated in the context of the lifetime costs of diabetes management, including insulin, monitoring devices, treatment of complications, and reduced quality of life.
Economic analyses suggest that successful islet cell transplantation that eliminates or significantly reduces the need for insulin and prevents complications could be cost-effective over a patient’s lifetime, despite high upfront costs. Personalized approaches that improve success rates and reduce complications could further enhance cost-effectiveness.
Future Directions and Emerging Innovations
The field of personalized islet cell transplantation continues to evolve rapidly, with numerous exciting innovations on the horizon that promise to further improve outcomes and expand access to this life-changing therapy.
Bioengineered Pancreatic Organoids
Researchers are developing three-dimensional pancreatic organoids that more closely mimic the structure and function of native pancreatic tissue. These organoids incorporate not only insulin-producing beta cells but also other islet cell types, supporting cells, and vascular networks. Personalized organoids could be generated from patient-specific stem cells or engineered to match individual immune profiles, potentially offering superior function and survival compared to isolated islet cells.
Combination Therapies and Multi-Modal Approaches
Emerging innovations in stem cell-derived islets, cell encapsulation, and gene editing offer hope for overcoming these barriers, and these advancements have the potential to improve graft survival, increase the availability of transplantable cells, and reduce dependence on immunosuppressive therapies, ultimately paving the way for more accessible, durable, and personalized diabetes treatments in the future.
Future personalized approaches will likely combine multiple strategies—such as gene-edited hypoimmunogenic cells, immunomodulatory biomaterials, optimized transplantation sites, and targeted immunotherapies—tailored to individual patient needs. This multi-modal approach could maximize the benefits of each strategy while minimizing limitations.
In Vivo Reprogramming and Regeneration
Rather than transplanting cells generated ex vivo, emerging research is exploring the possibility of reprogramming cells within the patient’s own body to become insulin-producing beta cells. This approach could eliminate many of the challenges associated with cell transplantation, including immune rejection, cell survival during isolation and transplantation, and the need for donor tissue. Personalized in vivo reprogramming strategies could target specific cell types based on individual patient characteristics.
Artificial Pancreas Integration
While islet cell transplantation aims to restore natural insulin production, integration with artificial pancreas systems and continuous glucose monitoring technologies could provide additional layers of glycemic control and safety. Personalized hybrid approaches might combine biological islet transplants with technological solutions, optimized based on individual patient needs, lifestyle, and residual beta cell function.
Expansion to Type 2 Diabetes and Other Conditions
The promising outcomes from recent clinical trials suggest that transplantation of iPSC- or ESC-derived islet cells could pave the way for more effective and broadly accessible treatment options, and this progress holds potential not only for individuals with type 1 diabetes but may also extend to type 2 diabetes treatment in the future.
The gentler pre-conditioning approaches being developed could make stem cell transplants a viable treatment for autoimmune disease such as rheumatoid arthritis and lupus, and non-cancerous blood conditions like sickle cell anemia, or for transplants of mismatched solid organs. The principles and technologies developed for personalized islet cell transplantation could have broad applications across regenerative medicine and transplantation.
Patient Selection and Personalized Treatment Algorithms
As personalized islet cell transplantation therapies become more sophisticated, developing algorithms to match patients with the most appropriate treatment approach will be crucial for optimizing outcomes and resource utilization.
Risk Stratification and Outcome Prediction
Comprehensive assessment of patient factors—including HLA profile, autoantibody status, history of hypoglycemia, presence of complications, immune system characteristics, and genetic markers—can help predict which patients are most likely to benefit from islet transplantation and which specific approach would be optimal. Machine learning models trained on large datasets of transplant outcomes are being developed to support these predictions.
Tailoring Treatment Intensity
Not all patients require the same level of intervention. Some patients with favorable immune profiles might achieve good outcomes with standard allogeneic islets and conventional immunosuppression, while others with high immunological risk might benefit from gene-edited hypoimmunogenic cells, encapsulation devices, or tolerance-inducing protocols. Personalized algorithms can guide these treatment decisions based on individual risk-benefit assessments.
Timing of Intervention
Pancreatic islet cell therapy not only helps treat hypoglycemic unawareness but may also help prevent kidney damage caused by diabetes if used early, before complications like diabetic nephropathy develop. Personalized approaches must consider the optimal timing for islet transplantation—balancing the benefits of early intervention to prevent complications against the risks and burdens of the procedure and immunosuppression.
Ethical Considerations and Patient Perspectives
As personalized islet cell transplantation therapies advance, important ethical considerations must be addressed to ensure equitable access, informed consent, and patient-centered care.
Access and Equity
Advanced personalized therapies may initially be expensive and available only at specialized centers, potentially creating disparities in access. Efforts must be made to ensure that these life-changing treatments become available to diverse patient populations regardless of socioeconomic status, geographic location, or other factors. Strategies to reduce costs, expand manufacturing capacity, and train healthcare providers at more centers will be essential.
Informed Consent and Shared Decision-Making
The complexity of personalized islet cell transplantation options requires robust informed consent processes and shared decision-making between patients and healthcare teams. Patients must understand the potential benefits, risks, alternatives, and uncertainties associated with different approaches. Decision aids and patient education materials tailored to individual literacy levels and cultural backgrounds can support informed choices.
Ethical Use of Genetic Technologies
The open questions that need to be addressed, and the ethical considerations connected with these novel forms of cell therapy for T1D include concerns about germline versus somatic cell editing, potential unintended consequences of genetic modifications, and the appropriate boundaries for human enhancement versus therapy. Transparent ethical frameworks and ongoing dialogue among scientists, clinicians, ethicists, and patients are essential as these technologies advance.
Global Perspectives and International Collaboration
Advancing personalized islet cell transplantation requires international collaboration to share knowledge, harmonize regulatory approaches, and address the global burden of diabetes.
Different countries have varying regulatory frameworks, healthcare systems, and resources for developing and implementing advanced cell therapies. International consortia and collaborative research networks are facilitating the exchange of data, protocols, and best practices. Harmonizing standards for cell manufacturing, quality control, and clinical trial design can accelerate progress and ensure that innovations developed in one region can benefit patients worldwide.
The global diabetes epidemic affects populations in both developed and developing countries, with varying genetic backgrounds, environmental factors, and healthcare infrastructure. Personalized approaches must be adaptable to diverse populations and settings, potentially requiring different strategies for different regions based on local resources, prevalent HLA types, and disease characteristics.
Conclusion: A Transformative Future for Diabetes Care
Avoiding the risks of chronic immunosuppression represents the next frontier, and several strategies have entered or are approaching clinical investigation, including immune-isolating islets, engineering immune-privileged islet implantation sites, rendering islets immune evasive, and inducing immune tolerance in transplanted islets, and leveraging these parallel progression paths will facilitate the wider clinical adoption of cell replacement therapies in diabetes care.
The future of personalized islet cell transplantation therapies is extraordinarily promising, with multiple converging innovations poised to transform diabetes treatment in the coming decades. From stem cell-derived beta cells and gene-edited hypoimmunogenic islets to advanced biomaterials and tolerance-inducing protocols, the field is rapidly moving toward therapies that can be tailored to individual patient needs while eliminating many of the current limitations of islet transplantation.
The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances. As these technologies mature and become more accessible, personalized islet cell transplantation has the potential to offer millions of people with diabetes freedom from insulin injections, protection from dangerous hypoglycemia, prevention of long-term complications, and dramatically improved quality of life.
The journey from laboratory research to widespread clinical implementation will require continued scientific innovation, clinical validation, regulatory approval, infrastructure development, and commitment to equitable access. However, the remarkable progress achieved in recent years provides strong reason for optimism that personalized islet cell transplantation will become a cornerstone of diabetes care, fundamentally changing the trajectory of this disease for future generations.
For more information on diabetes research and treatment advances, visit the National Institute of Diabetes and Digestive and Kidney Diseases, the American Diabetes Association, the JDRF, the International Pancreas and Islet Transplant Association, and Cell Stem Cell for the latest scientific publications in regenerative medicine.